TER Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Teradyne is not a clear buy right now for a beginner long-term investor, despite strong momentum and several bullish analyst updates. At $380.67, the stock is trading close to the upper end of its recent technical range, and the latest news points to decelerating Q2 revenue and EPS versus Q1, which makes the near-term setup less attractive for someone who wants to buy immediately and hold long term. The stock has upside potential, but based on the current price, mixed sentiment, and uneven earnings outlook, I would rate it as a hold rather than a direct buy today.
The chart trend is constructive. MACD histogram is positive and expanding, and the moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which confirms an uptrend. RSI_6 at 64.895 is neutral-to-mildly strong, not yet overbought. Price is above the pivot at 356.715 and approaching resistance at R1 393.86, so momentum remains positive but upside from here looks more limited in the short term. The technical trend is bullish, but the current price is not a low-risk entry for an impatient buyer.
["Multiple analysts raised price targets and several kept Buy/Outperform ratings.", "JPMorgan upgraded the stock to Overweight, citing valuation after the post-earnings selloff.", "Management highlighted continued strength in compute and memory testing, including HBM/DRAM.", "New merchant GPU customer supports the AI-driven test demand story.", "Congress trading shows one purchase and no sales in the last 90 days, a positive sign.", "Technical trend remains bullish with MACD expansion and bullish moving averages."]
["Q2 revenue guidance of $1.15B-$1.25B is below Q1 revenue of $1.28B.", "Q2 adjusted EPS guidance of $1.86-$2.15 is below Q1 EPS of $2.56.", "Shares fell more than 8% after the earnings-related update, showing investor concern.", "Hedge funds have been heavy sellers over the last quarter.", "Morgan Stanley stayed Equal Weight, suggesting limited conviction at current levels.", "The stock has already had a large year-to-date run, making upside harder to justify immediately."]
Latest quarter referenced: Q1. The company reported strong Q1 results, with management citing robust underlying demand trends in semiconductor test markets, especially in compute and memory testing. However, the most recent guidance implies a softer Q2 than Q1, with revenue expected to decline to $1.15B-$1.25B from $1.28B and adjusted EPS expected to fall to $1.86-$2.15 from $2.56. That indicates solid structural demand, but short-term growth is uneven rather than accelerating.
Analyst sentiment is broadly positive, but not uniformly bullish. Several firms raised price targets: Morgan Stanley to $387 with Equal Weight, Evercore to $370 with Outperform, Goldman Sachs to $350 with Buy, Citi to $400 with Buy, JPMorgan to $400 with Overweight, Baird to $350 with Outperform, Stifel to $390 with Buy, Evercore to $430 with Outperform, and UBS to $440 with Buy. The pattern shows higher targets and generally positive long-term views, but Morgan Stanley’s neutral stance and the mixed reaction to the earnings setup show Wall Street sees upside, yet not enough certainty for a strong immediate buy.
